Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis

Nature Chemical Biology

Volumn 9, Issue 8, 2013, Pages 499-506

  Wilson, Regina ^a   Kumar, Pradeep ^a   Parashar, Vijay ^a   Vilchèze, Catherine ^b   Veyron Churlet, Romain ^c,f   Freundlich, Joel S ^a   Barnes, S Whitney ^d   Walker, John R ^d   Szymonifka, Michael J ^a   Marchiano, Emily ^a   Shenai, Shubhada ^a   Colangeli, Roberto ^a   Jacobs, William R ^b   Neiditch, Matthew B ^a   Kremer, Laurent ^c,e   Alland, David ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CNRS   (France)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e INSERM   (France)

^f INSERM U1019   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ISONIAZID; MYCOLIC ACID; POLYKETIDE SYNTHASE; THIOPHENE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE OVEREXPRESSION; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84880924467     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1277     Document Type: Article

References (59)

1. Espinal, M.A. The global situation of MDR-TB. Tuberculosis (Edinb.) 83, 44-51 (2003
2. Mondal, R. & Jain, A. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg. Infect. Dis. 13, 1429-1431 (2007
3. Caminero, J.A., Sotgiu, G., Zumla, A. & Migliori, G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 10, 621-629 (2010
4. Kroon, A.M. & Van den Bogert, C. Antibacterial drugs and their interference with the biogenesis of mitochondria in animal and human cells. Pharm. Weekbl. Sci. 5, 81-87 (1983
5. Kohanski, M.A., Dwyer, D.J. & Collins, J.J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8, 423-435 (2010
6. Wei, J.R. et al. Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl. Acad. Sci. USA 108, 4176-4181 (2011
7. Jovetic, S., Zhu, Y., Marcone, G.L., Marinelli, F & Tramper, J. β-Lactam and glycopeptide antibiotics: First and last line of defense? Trends Biotechnol. 28, 596-604 (2010
8. Khoo, K.H. et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. J. Biol. Chem. 271, 28682-28690 (1996
9. Vilchèze, C. et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12, 1027-1029 (2006
10. Slayden, R.A. et al. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. 40, 2813-2819 (1996
11. Glickman, M.S., Cox, J.S. & Jacobs, W.R. Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000
12. Dubnau, E. et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. 36, 630-637 (2000
13. Bhatt, A., Molle, V., Besra, G.S., Jacobs, W.R. Jr. & Kremer, L. The Mycobacterium tuberculosis FAS-II condensing enzymes: Their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. Mol. Microbiol. 64, 1442-1454 (2007
14. Kremer, L., Baulard, A.R. & Besra, G.S. Genetics of mycolic acid biosynthesis. in Molecular Genetics of Mycobacteria (eds. Hatfull, G.F. & Jacobs, W.R. Jr.) 173-190 (ASM Press, 2000
15. Takayama, K., Wang, C. & Besra, G.S. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 18, 81-101 (2005
16. Barry, C.E. III et al. Mycolic acids: Structure, biosynthesis and physiological functions. Prog. Lipid Res. 37, 143-179 (1998
17. Brennan, P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 83, 91-97 (2003
18. Ojha, A.K., Trivelli, X., Guerardel, Y., Kremer, L. & Hatfull, G.F. Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms. J. Biol. Chem. 285, 17380-17389 (2010
19. Gavalda, S. et al. The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis. J. Biol. Chem. 284, 19255-19264 (2009
20. Portevin, D. et al. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc. Natl. Acad. Sci. USA 101, 314-319 (2004
21. Léger, M. et al. The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem. Biol. 16, 510-519 (2009
22. Carroll, P., Faray-Kele, M.C. & Parish, T. Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl. Environ. Microbiol. 77, 5040-5043 (2011
23. Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100, 12989-12994 (2003
24. Alland, D., Steyn, A.J., Weisbrod, T., Aldrich, K. & Jacobs, W.R. Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182, 1802-1811 (2000
25. Maddry, J.A. et al. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb.) 89, 354-363 (2009
26. Ananthan, S. et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb.) 89, 334-353 (2009
27. Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797-1809 (2012
28. Telenti, A. et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3, 567-570 (1997
29. Onodera, Y., Tanaka, M. & Sato, K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 47, 447-450 (2001
30. Trivedi, O.A. et al. Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature 428, 441-445 (2004
31. Freundlich, J.S. et al. Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 4, 241-248 (2009
32. Reddy, V.M., Einck, L., Andries, K. & Nacy, C.A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54, 2840-2846 (2010
33. Siddiqi, S.H., Libonati, J.P. & Middlebrook, G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 13, 908-912 (1981
34. Safi, H., Sayers, B., Hazbon, M.H. & Alland, D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob. Agents Chemother. 52, 2027-2034 (2008
35. Middlebrook, G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am. Rev. Tuberc. 65, 765-767 (1952
36. Siddiqi, S., Takhar, P., Baldeviano, C., Glover, W. & Zhang, Y. Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 2100-2104 (2007
37. Gumbo, T. et al. Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51, 2329-2336 (2007
38. Gumbo, T. et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195, 194-201 (2007
39. Wallis, R.S. et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43, 2600-2606 (1999
40. Falzari, K. et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 1447-1454 (2005
41. Boechat, N. et al. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain. J. Med. Chem. 54, 5988-5999 (2011
42. Morris, G.M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009
43. Trott, O. & Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010
44. Šali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993
45. Phetsuksiri, B. et al. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob. Agents Chemother. 43, 1042-1051 (1999
46. Kremer, L. et al. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278, 20547-20554 (2003
47. Roujeinikova, A. et al. X-ray crystallographic studies on butyryl-ACP reveal flexibility of the structure around a putative acyl chain binding site. Structure 10, 825-835 (2002
48. Parris, K.D. et al. Crystal structures of substrate binding to Bacillus subtilis holo-(acyl carrier protein) synthase reveal a novel trimeric arrangement of molecules resulting in three active sites. Structure 8, 883-895 (2000
49. Lee, R.E. et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172-187 (2003
50. Jackson, M., Crick, D.C. & Brennan, P.J. Phosphatidylinositol is an essential phospholipid of mycobacteria. J. Biol. Chem. 275, 30092-30099 (2000
51. Veyron-Churlet, R., Zanella-Cleon, I., Cohen-Gonsaud, M., Molle, V. & Kremer, L. Phosphorylation of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. J. Biol. Chem. 285, 12714-12725 (2010
52. Stover, C.K. et al. New use of BCG for recombinant vaccines. Nature 351, 456-460 (1991
53. Kim, P. et al. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J. Med. Chem. 52, 1329-1344 (2009
54. van Soolingen, D., Hermans, P.W., de Haas, P.E., Soll, D.R. & van Embden, J.D. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29, 2578-2586 (1991
55. Slayden, R.A. & Barry, C.E. III. Analysis of the lipids of Mycobacterium tuberculosis. Methods Mol. Med. 54, 229-245 (2001
56. Seeliger, J.C. et al. Elucidation and chemical modulation of sulfolipid-1 biosynthesis in Mycobacterium tuberculosis. J. Biol. Chem. 287, 7990-8000 (2012
57. Domenech, P. & Reed, M.B. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: Implications for virulence studies. Microbiology 155, 3532-3543 (2009
58. Alibaud, L. et al. A Mycobacterium marinum TesA mutant defective for major cell wall-associated lipids is highly attenuated in Dictyostelium discoideum and zebrafish embryos. Mol. Microbiol. 80, 919-934 (2011
59. DeLano, W.L. The PyMOL Molecular Graphics System (DeLano Scientific, San Carlos, California, USA, 2002